









Markets
/
Stocks
/
nasdaq-inm
/

InMed Pharmaceuticals Inc

INM

View Detailed Chart

2.390USD

-0.040-1.65%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

2.89MMarket Cap

LossP/E TTM



InMed Pharmaceuticals Inc

2.390

-0.040-1.65%

Overview Company Financials

Financials

Intraday

30m

Today

-1.65%

5 Days

-9.47%

1 Month

-17.87%

6 Months

-22.15%

Year to Date

-49.58%

1 Year

-29.54%

View Detailed Chart

Agency Rating

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(8)

Neutral(2)

Buy(0)

Indicators

Sell(2)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.064

Sell

RSI(14)

38.460

Neutral

STOCH(KDJ)(9,3,3)

19.299

Neutral

ATR(14)

0.147

Low Volatility

CCI(14)

-233.004

Oversold

Williams %R

88.419

Oversold

TRIX(12,20)

-0.550

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.530

Sell

MA10

2.594

Sell

MA20

2.687

Sell

MA50

2.808

Sell

MA100

2.744

Sell

MA200

3.530

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.

Ticker SymbolINM

CompanyInMed Pharmaceuticals Inc

CEOMr. Eric A. Adams

Websitehttps://www.inmedpharma.com/